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 Introduction 
 Both stroke and myocardial infarction (MI) are among 
the leading causes of long-term disability and mortality 
in Western Europe. Similar risk factors have been de-
scribed for both diseases. Arterial hypertension, dyslip-
idemia, diabetes mellitus, smoking habits, obesity, de-
pression and family history have all been identified as 
significant risk factors for the development of cardiovas-
cular disease and stroke  [1, 2] .
 Stroke is associated with a moderate mortality rate. 
Most patients usually survive their first ischemic stroke, 
but data demonstrate that many of these patients are se-
verely impaired suffering from disability  [3] . Thus, stroke 
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 Abstract 
 Background: There is a lack of the generic data comparing 
the influence of different diseases on health-related quality 
of life (HrQoL) in a representative sample of primary care pa-
tients.  Methods: Patient data were collected in the DETECT 
(Diabetes Cardiovascular Risk Evaluation: Targets and Essen-
tial Data for Commitment of Treatment) study including 
55,000 patients.  Results: 3,109 patients (33.3% female) with 
myocardial infarction (MI), stroke or both were compared to 
patients with a wide range of other diagnoses. Stroke and MI 
patients revealed a lower HrQoL as compared to patients 
with other diagnoses. Stroke was associated with strongest 
quality of life reduction. Multivariate analysis revealed sev-
eral different determining factors.  Conclusions: The reduc-
tion of HrQoL of patients with MI and stroke is primarily de-
termined by the CNS insult. These data provide further evi-
dence that early diagnosis and treatment of cardiovascular 
risk factors is essential to reduce subsequent stroke. 
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is a leading cause of long-term disability in the USA and 
Europe  [4] . According to data from the WHO, the stroke 
burden is predicted to increase from 38 million disabili-
ty-adjusted life years in 1990 to 61 million in 2020.
 MI is part of a disease group termed coronary heart 
disease that also includes unstable angina pectoris, sud-
den death and MI  [5] . Coronary heart disease is the lead-
ing cause of death in adults in the USA, accounting for 
about one third of all deaths in subjects over the age of 35 
years  [4] . In Germany, MI was the leading cause of death 
in 2004.
 Furthermore, the longterm course and outcome of 
both, MI and stroke, is frequently associated with in-
creased rates of depression, anxiety and social isolation, 
known to reduce, among other factors, the quality of life 
in these patients  [6, 7] .
 In recent years, the introduction of quality of life ques-
tionnaires has led to an improved understanding of pa-
tient-reported health outcomes in clinical studies. Both 
diseases influence patients in many different ways. This 
multidimensional influence has not been well evaluated 
by standard clinical outcome measures. In this study, the 
EuroQol questionnaire EQ-5D  [8] was used. The Euro-
Qol questionnaire is an instrument used to describe and 
evaluate health states. It is a standardized instrument 
which provides a simple descriptive health profile with 
the dimensions mobility, self-care, usual activities, pain/
discomfort and anxiety/depression.
 Since both diseases are associated with similar risk 
factors, questions have arisen as to whether there is a dif-
ference in patient-related quality of life after such an 
event. Therefore, we analyzed data from a large epide-
miological study (DETECT, Diabetes Cardiovascular 
Risk-Evaluation: Targets and Essential Data for Commit-
ment of Treatment; www.detect-studie.de) that drew 
upon more than 55,000 patients from the German pri-
mary care system. There were 3,109 patients with stroke, 
MI or both and vascular risk factors, and their influence 
on health-related quality of life (HrQoL) was evaluated in 
subgroups of patients based on whether they had experi-
enced either MI or stroke or both.
 Material and Methods 
 Study Design 
 The DETECT study is an epidemiological study in 3 stages 
conducted in the German primary care system. Initially, in 2003, 
a primary care provider survey was performed. The second stage 
of the study consisted of a cross-sectional point prevalence study 
of unselected consecutive patients who sought care in these set-
tings. Patient sampling was performed on a target half day (in 
September 2003). Patients were informed by posters and leaflets 
about the possibility of study participation. All patients had to 
provide informed consent before participation. They were then 
asked to complete a self-report patient questionnaire. In addition, 
a structured doctor’s interview and a thorough physical examina-
tion were performed. Blood samples were also drawn and ana-
lyzed in a random subset of patients. The third phase of the study 
consisted of 2 follow-up examinations (after 1 and 5 years) of 
those patients randomly assigned to laboratory workup. The fol-
low-up visits were similar in setup to the initial visit. The  DETECT 
study was approved by the ethical committee of the TU Dresden 
(AZ: EK149092003; Date: September 16, 2003). The design and 
sampling of the original study have been described in greater de-
tail  [9–11] . For more information see also the website (http://
www.detect-studie.de).
 On the study target day, a total of 59,403 eligible patients were 
present in 3,188 participating primary care offices. Of these, 3,607 
patients refused participation and for 278 patients, a physician’s 
appraisal was not available. Thus, the present paper is based on 
data from 55,518 patients (response rate: 93.5%) from the cross-
sectional part of the DETECT study. We analyzed HrQoL in the 
group of patients without MI or stroke, in those with either of the 
diseases alone as well as in patients with both diseases.
 Together with clinicians we selected a set of certain risk pa-
rameters that may have an influence on the risk of stroke or MI. 
These included arterial hypertension, diabetes, dyslipidemia, 
atrial fibrillation, carotid artery stenosis, smoking habits and 
body mass index (BMI) and were obtained using standard mea-
surements. In addition, the Depression Screening Questionnaire 
 [12] was used to evaluate the presence of lifetime, current and for-
mer depression.
 Health-Related Quality of Life 
 HrQoL was evaluated using the generic instrument EQ-5D  [8] . 
Applicable to a wide range of health conditions and treatments, 
the EQ-5D not only generates a health profile but is also capable 
of expressing HrQoL as a single index value (utility value). There-
fore, it can be used for both clinical and economic evaluations of 
health care. It includes a descriptive system with 5 dimensions 
and a visual analogue scale (EQ VAS). The 5 dimensions are mo-
bility, self-care, usual activities, pain/discomfort and anxiety/de-
pression. All dimensions are subdivided into 3 levels. These re-
sponse levels indicate different categories: no problems, some/
moderate problems and extreme problems. In calculating the re-
sponses, there exist 243 (3 5 = 243) possible different health states. 
The EQ-5D summary score was calculated according to the cor-
responding scoring algorithms for the German population estab-
lished by Greiner et al.  [13] .
 Data Entry and Statistical Analysis 
 Data were analyzed using Stata 10.0 (StataCorp  [14] ). Results 
are presented as means (SD) or number of cases (percentages) as 
appropriate. Group comparisons of the EQ-5D score were esti-
mated using a linear regression framework. The assessment of 
independent predictors of HrQoL was performed using multivar-
iate regression analysis with forward selection. The variables used 
in univariate and multivariate analyses were specified based on 
the opinions of a consensus among 3 specialists and data from 
previous studies. Variables were screened by means of the Spear-
 Bach  /Riedel  /Pieper  /Klotsche  /Dodel  /
Wittchen  
Cerebrovasc Dis 2011;31:68–76 70
man rank correlation (p = 0.10) with regard to their possible im-
pact on health status. Of those variables that proved significant in 
bivariate analysis, reasonable variables were chosen for multiple 
linear regression with EQ VAS and EQ-5D index scores as depen-
dent variables. We used a stepwise forward mode to include inde-
pendent predictors with a significance level of   = 0.05. Multi-
variate logistic regression was applied to test for a significant pre-
dictor of single dimensions of the EQ-5D index. The 5 dimension 
variables were dichotomized into ‘having problems’ or ‘having 
not’ (e.g. no problems with daily activities equals 0, some prob-
lems or severe problems with daily activities equals 1). Standard 
errors and 95% CI were estimated using the bootstrap technique 
to account for the skewed distribution of the EQ-5D score. Data 
were weighted to adjust for nonresponse, regional distribution 
and attrition.
 Results 
 Patient Characteristics 
 A total of 55,518 patients were included in the study; 
2,181 patients had suffered a MI, 783 patients were diag-
nosed as having had a stroke and 145 patients had suffered 
both. The mean age was 67.4 years (SD = 10.2 years) for pa-
tients with MI, compared to 68.2 years (SD = 10.8 years) for 
patients who had suffered a stroke, and a mean age of 70.3 
years (SD = 8.4 years) for patients who had suffered both. 
59.2% of all patients were female. Amongst the patients 
with MI, 29.5% were females, compared to 44.0% among 
stroke patients and 25.9% of those who had both stroke and 
MI. Further patient characteristics are provided in  table 1 .
Table 1.  Characteristics of the study population
Total Neither stroke
nor MI
MI Stroke MI and stroke
Total number 55,518 (100.0) 52,409 (94.4) 2,181 (3.9) 783 (1.4) 145 (0.3)
Age, years 53.9817.3 53.0817.3 67.4810.2 68.3810.8 70.388.4
Female gender 32,839 (59.2) 31,810 (60.7) 640 (29.5) 352 (44.0) 37 (25.9)
Smoking status
Never smoked 28,282 (53.3) 27,010 (54.0) 831 (40.1) 386 (51.8) 55 (37.7)
Former smoker 10,812 (20.6) 9,539 (19.2) 962 (45.8) 250 (34.1) 61 (43.9)
Current smoker 13,504 (26.1) 13,086 (26.8) 288 (14.2) 106 (14.1) 24 (18.5)
Pack years (current smokers)
1–19 8,116 (60.8) 7,856 (60.7) 180 (65.1) 64 (59.1) 16 (74.2)
20–39 4,732 (36.6) 4,598 (36.7) 91 (32.5) 36 (38.0) 7 (25.8)
40–59 310 (2.4) 302 (2.4) 5 (2.0) 3 (2.9) 0 (0.0)
60–79 29 (0.2) 29 (0.2) 0 (0.0) 0 (0.0) 0 (0.0)
BMI 26.985.3 26.885.3 28.184.5 27.985.1 28.484.1
Diabetes mellitus1 8,465 (14.7) 7,338 (13.5) 765 (34.4) 284 (34.9) 78 (49.8)
Hypertension2 31,635 (56.4) 28,699 (54.1) 2,089 (95.4) 707 (90.1) 140 (95.3)
Hyperlipidemia 16,178 (29.5) 14,211 (27.5) 1,436 (66.3) 428 (54.7) 103 (70.3)
Atrial fibrillation 1,860 (3.4) 1,504 (2.9) 218 (10.2) 113 (14.9) 25 (17.4)
Carotid artery stenosis 801 (1.4) 503 (1.0) 153 (6.8) 116 (15.1) 29 (17.8)
Anxiety 3,082 (5.6) 2,882 (5.6) 128 (6.2) 61 (8.0) 11 (8.8)
Depression
Lifetime depression 10,424 (20.7) 9,590 (20.2) 537 (28.0) 242 (35.3) 55 (48.0)
Current depression 7,759 (15.5) 7,134 (15.1) 406 (21.5) 178 (26.0) 41 (36.2)
Former depression 2,665 (5.2) 2,456 (5.1) 131 (6.6) 64 (9.3) 14 (11.8)
Sexual dysfunction 1,285 (2.4) 1,062 (2.1) 153 (7.2) 52 (6.8) 18 (12.4)
Mental disability days (yes)3 3,061 (6.6) 2,825 (6.4) 147 (8.9) 71 (13.5) 18 (20.5)
Mental disability days, days 0.783.5 0.783.4 1.184.5 1.685.4 2.286.4
Physical disability days (yes)3 10,972 (23.6) 10,326 (23.4) 463 (27.9) 148 (27.2) 35 (38.0)
Physical disability days, days 2.285.7 2.185.6 3.287.2 3.487.5 4.888.8
Values denote numbers with percentages weighted for attri-
tion and nonresponse in parentheses, or means 8 SD. Valid ob-
servations – smoking status: n = 52,598; pack years for current 
smokers: n = 13,190; BMI: n = 54,939; depression: n = 51,206; men-
tal disability days: n = 47,459; physical disability days: n = 46,882.
1 Clinicians rating ‘definite’ or plasma glucose >125 mg/dl or 
antidiabetic treatment.
2 Clinicians rating ‘definite’ or blood pressure ≥140/90 mm Hg 
or antihypertensive treatment.
3 Disability days in last 4 weeks.
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 Differences in HrQoL 
 Next, we evaluated EQ-5D values within these differ-
ent groups. In each EQ-5D dimension, there is an in-
crease in reported problems in patients with MI, stroke 
and both diseases as compared to patients without either 
of these diseases. In detail, the mean EQ-5D score was 
0.74 in patients without stroke or MI, compared to 0.66 
(p  ! 0.001) in patients with MI and 0.62 (p  ! 0.001) in pa-
tients with stroke. The EQ-5D values were significantly 
lower in patients having suffered both (0.57). A similar 
pattern was found for each of the 5 dimensions of mobil-
ity, self- care, usual activities, pain/discomfort and anxi-
ety depression. Patients with a history of MI, stroke or 
both diseases reported significantly higher proportions 
of moderate and extreme problems compared to patients 
without stroke or MI. Detailed results can be found in 
 table 2 .
 Risk Factors for Cerebrovascular Disease and 
Associated HrQoL 
 Table 3 provides an overview of the distribution of es-
tablished risk factors for cerebrovascular disease for pa-
tients without stroke or MI, patients with stroke, MI and 
both diseases and the associated quality of life within 
each of these groups. Patients suffering from stroke and 
MI had the lowest quality of life across risk factor levels 
as compared to patients without stroke and MI (p  ! 0.001) 
and patients with either stroke or MI. The HrQoL de-
creased with increasing risk factor levels in general. Pa-
tients with stroke or MI also reported lower HrQoL (p  ! 
0.001) in contrast to patients without both diseases.
 Multivariate Analysis to Evaluate the Association of 
Quality of Life with Risk Factor 
 Based on clinical experience we selected several risk fac-
tors known to influence HrQoL. These included age, sex, 
sexual dysfunction, carotid artery stenosis, BMI, anxiety/
Table 2.  Reported problems in EQ-5D dimensions and VAS score in patients with and without MI and/or stroke
EQ-5D dimensions No MI or stroke MI Stroke MI and stroke
Mobility
No problems (0) 35,292 (73.2) 1,012 (51.9) 278 (41.3) 44 (34.4)
Some/moderate problems (1) 12,836 (26.6) 928 (48.1) 390 (58.0) 73 (63.3)
Extreme problems (2) 54 (0.1) 0 (0.0) 4 (0.6) 3 (2.4)
Any problems (1 + 2) 12,890 (26.8) 928 (48.1) 394 (58.7) 76 (65.6)
Self-care
No problems (0) 44,917 (92.3) 1,573 (80.6) 462 (68.7) 74 (58.2)
Some/moderate problems (1) 3,392 (7.1) 348 (18.0) 197 (28.0) 35 (29.9)
Extreme problems (2) 282 (0.6) 28 (1.4) 22 (3.3) 11 (12.0)
Any problems (1 + 2) 3,674 (7.7) 376 (19.4) 219 (31.3) 46 (41.8)
Usual activities
No problems (0) 37,179 (76.7) 1,134 (58.1) 336 (49.9) 50 (40.1)
Some/moderate problems (1) 10,446 (21.8) 737 (38.3) 297 (43.8) 57 (47.4)
Extreme problems (2) 698 (1.5) 71 (3.6) 43 (6.4) 12 (12.5)
Any problems (1 + 2) 11,144 (23.3) 808 (41.9) 340 (50.2) 69 (59.9)
Pain/discomfort
No problems (0) 16,696 (34.9) 407 (21.1) 137 (20.7) 14 (11.6)
Some/moderate problems (1) 27,197 (56.9) 1,256 (65.2) 441 (65.2) 81 (67.7)
Extreme problems (2) 3,786 (8.2) 252 (13.7) 95 (14.2) 23 (20.7)
Any problems (1 + 2) 30,983 (65.1) 1,508 (78.9) 536 (79.3) 104 (88.4)
Anxiety/depression
No problems (0) 34,116 (71.5) 1,328 (69.1) 388 (59.1) 69 (54.6)
Some/moderate problems (1) 12,155 (25.8) 515 (27.8) 245 (36.6) 43 (38.6)
Extreme problems (2) 1,250 (2.7) 58 (3.1) 28 (4.3) 7 (6.8)
Any problems (1 + 2) 13,405 (28.5) 573 (30.9) 273 (40.9) 50 (45.4)
EQ VAS score 0.74 (0.18) 0.66 (0.19) 0.62 (0.20) 0.57 (0.20)
V alues denote numbers with percentages in parentheses unless otherwise indicated. Valid patient ratings: mobility (n = 50,914); 
self-care (n = 51,341); usual activity (n = 51,060); pain/discomfort (n = 50,385); anxiety/depression (n = 50,202).
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panic attacks, diabetes mellitus, depression, smoking sta-
tus, blood pressure, hypercholesterinemia and atrial fibril-
lation. The association between risk factors and HrQoL 
was studied for patients without stroke or MI, and patients 
with stroke, MI and both diseases. The resulting   values 
for the corresponding variables are given in  table 4 . De-
pression is associated with lower HrQoL across the 4 
groups. Interestingly, however, lower HrQoL is associated 
with an increasing BMI in patients without history of 
stroke and MI, whereas patients with a history of stroke 
and MI have higher HrQoL that increases with BMI. The 
onset of risk factors is significantly associated with lower 
quality of life in patients without stroke and MI. In patients 
with MI and stroke, the model was able to explain only 40% 
of the variability. However, the small number of patients in 
this group (n = 145) needs to be considered. For all other 
groups, this model only explains 26–32% of the variability.
 Discussion 
In this representative sample of over 55,000 primary 
care patients we find, consistent with previous studies 
in partly highly selective samples [6, 15–18] that (1) MI 
as well as stroke are associated with significantly stron-
ger reduction in quality of life than other illnesses. (2) 
Beyond these confirmative findings, however, we could 
show that stroke in particular appears to be greatest 
contributor to HrQoL, revealing that any pattern of co-
morbidity with stroke and in particular the combina-
tion of MI and stroke is associated with significantly 
stronger reduction in HrQoL. This leads to our conclu-
sion the reduction in quality of life and functioning sta-
tus are largely driven by the CNS complications of 
stroke. 
 We were able to identify several risk factors that influ-
ence differences in EQ-5D outcome when comparing 
stroke and MI. Amongst these is depression, but also 
smoking and mean systolic arterial blood pressure.
 These data provide further evidence that early diagno-
sis and treatment of cardiovascular risk factors is essen-
tial to reduce subsequent stroke in patients from the Ger-
man primary care system. It is most important to under-
line the problems associated with continued smoking. In 
addition, nicotine abuse was associated with reduced 
scores in quality of life. The same holds true for mean 
systolic blood pressure, which not only is known to in-
crease the risk of renewed insult and other events, but also 
has a considerable impact on HrQoL.
 Furthermore, it is obvious that, in addition to treat-
ment of associated risk factors, it is essential to consider 
the possibility of depression and anxiety following stroke 
in primary care. This might be especially difficult to de-
termine in patients with affected language, but our data 
detected a considerable influence of both anxiety and de-
pression on HrQoL. It needs to be noticed that for pa-
tients with aphasia there is a specific questionnaire to be 
used to detect depression. Unfortunately, it was not ap-
plied in this study.
 Interestingly, in our study the influence of depression 
is independent of MI or stroke, which indicates that de-
pression is a problem in both diseases. It needs to be con-
sidered, however, that presence of depression directly in-
fluences HrQoL. Depression is a known independent risk 
factor. Therefore, early diagnosis and consequent therapy 
should be considered, especially during ambulatory care 
 [19, 20] . This may not only increase the quality of life of 
individual patients, but may also be important in cost-
effectiveness. Patients with depression are known to suf-
fer from comorbidities that increase financial burden due 
to a higher number of disability days and early retire-
ment, amongst others  [21, 22] . Therefore, considering and 
evaluating depression/anxiety in patients with MI or 
stroke seems important to avoid long disease duration 
and unnecessary complications.
 Furthermore, we detected an association between 
HrQoL and BMI. The control group demonstrated a neg-
ative correlation between BMI and EQ-5D values, i.e. the 
lower the BMI status, the higher the HrQoL. In contrast, 
patients with MI and stroke demonstrated increasing 
EQ-5D values with increasing BMI scores. This associa-
tion tends to change to a negative correlation by control-
ling for other risk conditions, but it fails statistical sig-
nificance. In contrast, patients with MI or stroke demon-
strated increasing EQ-5D values with increasing body 
weight. Currently, we do not have a data-based explana-
tion for this finding.
 Our univariate regression analysis reveals significant 
influences of almost all risk factors imputed. However, 
one needs to consider the high number of patients par-
ticipating in this group. From a statistical point of view, 
this renders even small effects statistically significant. 
Looking at these data from a clinical point of view, it 
seems likely that at least changes in BMI group as well as 
presence of diabetes, hyperlipidemia and hypertension 
explain some of the observed variability. These are, in 
general, associated with negative influences on quality of 
life. In line with this argumentation is the observation 
that smoking does not significantly contribute to chang-
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es in quality of life as there is a direct and positive influ-
ence of smoking on wellbeing.
 Despite the fact that the study design was carefully 
chosen and a large number of patients were included in 
this study, there are some limitations associated with it. 
First, the physicians who performed the examinations of 
the patients did not receive a special training in how to 
rate them. This inevitably led to problems with scoring 
patients. The data quality could have been enhanced by 
compulsory trainings; however, the goal was to reflect 
the regular treatment of patients in primary care. Fur-
thermore, no specific scores were applied to measure the 
severity or the disability of the neurologic deficit. Sec-
ond, we only assessed the presence or absence of a dis-
ease, but there was no time scale informing us as to when 
a certain disease was diagnosed and how it was diag-
nosed according to predefined scales. Third, the study 
was performed in a cross-sectional design. The study 
sample was sufficiently large to provide a representative 
sample for Germany. However, patients with very severe 
or fatal MI or stroke were not included in this study, 
which may have biased its results. In addition, HrQoL 
was measured, but from our data it cannot directly be 
linked to the sequences of a given disease. It may have 
Table 4.  Uni- and multivariate analyses to evaluate the association of several risk factors with HrQoL
No MI or stroke MI
univariate regression model m ultivariate regression model1 univariate regression model multivariate regression model1 
 95% CI  95% CI  95% CI  95% CI
R2 0.26 0.32
Age
18–44 years (ref.) (ref.) (ref.) (ref.)
45–64 years –0.06 (–0.07, –0.06)* –0.04 (–0.05, –0.04)* –0.10 (–0.14, –0.06)* –0.06 (–0.10, –0.02)*
65+ years –0.10 (–0.11, –0.10)* –0.08 (–0.09, –0.08)* –0.12 (–0.16, –0.07)* –0.10 (–0.15, –0.06)*
Gender
Female (ref.) (ref.) (ref.) (ref.)
Male 0.02 (0.02, 0.03)* 0.03 (0.02, 0.03)* 0.07 (0.06 , 0.09)* 0.05 (0.03, 0.07)*
Smoking status
Never smoked (ref.) (ref.) (ref.) (ref.)
Former smoker –0.01 (–0.01, 0.00)* –0.01 (–0.01, 0.00)* 0.02 (0.00, 0.05)*
Current smoker 0.01 (0.00, 0.01)* –0.01 (–0.02, –0.01)* –0.02 (–0.06, 0.01) –0.03 (–0.06, –0.01)*
BMI score
0–20 (ref.) (ref.) (ref.) (ref.)
20.01–25 0.00 (0.00, 0.01) 0.12 (0.04, 0.21)* 0.03 (0.01, 0.06)*
25.01–30 –0.03 (–0.03, –0.02)* –0.01 (–0.02, –0.01)* 0.12 (0.04, 0.21)* 0.03 (0.01, 0.05)*
30.01–35 –0.06 (–0.07, –0.05)* –0.03 (–0.04, –0.03)* 0.09 (0.01, 0.18)*
35.01–40 –0.08 (–0.09, –0.07)* –0.05 (–0.06, –0.04)* 0.11 (0.00, 0.21)*
>40 –0.10 (–0.11, –0.08)* –0.06 (–0.07, –0.04)* 0.02 (–0.09, 0.13)
Diabetes mellitus2 –0.05 (–0.06, –0.05)* –0.04 (–0.06, –0.03)* –0.02 (–0.04, –0.01)*
Hypertension3 –0.06 (–0.07, –0.06)* –0.01 (–0.02, –0.01)* –0.03 (–0.07, 0.01)
Hyperlipidemia –0.05 (–0.05, –0.04)* –0.01 (–0.01, 0.00)* 0.00 (–0.02, 0.02)
Atrial fibrillation –0.07 (–0.08, –0.06)* –0.02 (–0.03, –0.01)* –0.07 (–0.11, –0.03)*
Carotid artery stenosis –0.08 (–0.10, –0.07)* –0.03 (–0.04, –0.01)* –0.04 (–0.08, –0.01)* –0.05 (–0.08, –0.02)*
Anxiety –0.12 (–0.13, –0.12)* –0.06 (–0.07, –0.06)* –0.08 (–0.11, –0.04)* –0.04 (–0.07, 0.00)*
Depression
No depression (ref.) (ref.) (ref.) (ref.)
Lifetime depression –0.18 (–0.18, –0.17)* –0.12 (–0.13, –0.12)* –0.17 (–0.19, –0.15)* –0.12 (–0.14, –0.10)*
Current depression –0.20 (–0.20, –0.20)* –0.19 (–0.21, –0.17)*
Former depression –0.06 (–0.07, –0.06)* –0.03 (–0.06, 0.00)*
Sexual dysfunction –0.06 (–0.07, –0.04)* –0.05 (–0.08, –0.01)*
Mental disability days (yes)4 –0.20 (–0.21, –0.19)* –0.08 (–0.09, –0.07)* –0.21 (–0.24, –0.18)* –0.08 (–0.12, –0.05)*
Physical disability days (yes)4 –0.12 (–0.13, –0.12)* –0.08 (–0.09, –0.08)* –0.15 (–0.17, –0.13)* –0.10 (–0.12, –0.08)*
* Significant at p < 0.05. 1 Multivariate regression model: stepwise variable selection. 2 Clinicians rating ‘definite’ or plasma glucose >125 mg/dl or anti-
diabetic treatment. 3 Clinicians rating ‘definite’ or blood pressure >140/90 mm Hg or antihypertensive treatment. 4 Disability days in last 4 weeks.
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been possible that confounding variables influenced 
HrQoL. We tried to account for this by including the 
days that patients were unable to work as an indirect 
measure of their disability. This may serve as a possible 
surrogate parameter to account for the medical status 
related to the index diseases. Under the assumption that 
there is a random noise of comorbidity, this may allow 
one to impute quality of life to HrQoL. As can be seen 
from  table  1 , these values are very similar across the 
groups. Therefore, at least the surrogate parameter dem-
onstrates a random noise of comorbidity.
 In summary, we conclude from our data that the 
HrQoL of patients who have had an MI and stroke is pri-
marily determined by the CNS complications of stroke. 
We were able to identify several risk factors that influ-
ence differences in outcome when comparing stroke and 
MI.
 Acknowledgment 
 DETECT is supported by an unrestricted educational grant 
from Pfizer GmbH, Karlsruhe, Germany. 
Stroke MI and stroke
univariate regression model multivariate regression model1 univariate regression model  multivariate regression model1
 95% CI  95% CI   95% CI  95% CI
0.26 0.41
(ref.) (ref.) (ref.) (ref.)
–0.05 (–0.13, 0.04) –0.09 (–0.17, –0.01)* 0.05 (–0.02, 0.13)
–0.07 (–0.15 , 0.01) –0.13 (–0.21, –0.05)* – –
(ref.) (ref.) (ref.) (ref.)
0.06 (0.03, 0.10)* 0.04 (–0.04, 0.12)
(ref.) (ref.) (ref.) (ref.)
0.04 (0.00, 0.08)* 0.04 (–0.06, 0.14)
0.02 (–0.03, 0.06) –0.05 (–0.10, 0.00)* –0.13 (–0.26, –0.01)* –0.12 (–0.24, –0.01)*
(ref.) (ref.) (ref.) (ref.)
0.11 (–0.04, 0.26) 0.27 (0.18, 0.37)*
0.10 (–0.05, 0.25) 0.38 (0.34, 0.42)*
0.10 (–0.06, 0.25) 0.25 (0.17, 0.32)* –0.09 (–0.16, –0.02)*
0.05 (–0.10, 0.19) 0.36 (0.19, 0.54)*
–0.01 (–0.18, 0.16) –0.07 (–0.14, –0.01)* – –
–0.04 (–0.08, –0.01)* –0.03 (–0.06, –0.01)* –0.03 (–0.10, 0.03)
–0.01 (–0.06, 0.04) 0.10 (–0.03, 0.23)
0.02 (–0.02, 0.05) 0.06 (–0.03, 0.15)
–0.03 (–0.08, 0.02) –0.12 (–0.25, 0.01)
–0.02 (–0.07, 0.03) 0.04 (–0.04, 0.13)
–0.11 (–0.17, –0.06)* –0.11 (–0.23, 0.01)
(ref.) (ref.) (ref.) (ref.)
–0.17 (–0.20, –0.14)* –0.14 (–0.17, –0.11)* –0.20 (–0.29, –0.12)* –0.16 (–0.23, –0.08)*
–0.19 (–0.22, –0.16)* –0.24 (–0.31, –0.17)*
–0.03 (–0.08, 0.02) 0.03 (–0.05, 0.10)
–0.07 (–0.12, –0.01)* –0.04 (–0.16, 0.09)
–0.16 (–0.21, –0.11)* –0.09 (–0.14, –0.04)* –0.12 (–0.22, –0.02)*
–0.13 (–0.17, –0.08)* –0.07 (–0.11, –0.03)* –0.15 (–0.22, –0.09)* –0.11 (–0.17, –0.04)*
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